Final Results and CEO Succession

Summary by AI BETAClose X

Venture Life Group PLC announced its final results for the seventeen-month period ended May 31, 2026, reporting revenues of £50.0 million, a 16.0% increase on a proforma basis driven by volume. The company successfully divested its contract development and manufacturing operations for €62 million and its oral care brands for up to £4.5 million, transforming into a pure-play consumer healthcare business. Adjusted EBITDA rose to £7.9 million, though the adjusted EBITDA margin decreased to 15.7% due to temporary cost base de-leveraging. The Group posted a profit after tax of £3.4 million, a significant improvement from a £0.3 million loss in the prior period, and ended the period with £11.5 million in cash reserves and no drawn debt. Post-period, the company acquired the FemiClear and CUROXEN brands for $23.0 million, and announced the upcoming transition of its CEO, Jerry Randall, to be succeeded by CFO Daniel Wells.

Disclaimer*

UK 100

Latest directors dealings